within Pharmacolibrary.Drugs.ATC.A;

model A11CC01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.6,
    Cl             = 8.333333333333334e-09,
    adminDuration  = 600,
    adminMass      = 50000 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0005,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0005,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A11CC01</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Ergocalciferol, also known as vitamin D2, is a fat-soluble vitamin used to treat or prevent vitamin D deficiency and hypoparathyroidism. It is an approved drug still used today for these indications. It functions by increasing the absorption of calcium and phosphorus in the body, thus supporting bone health.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for healthy adult subjects; no reliable quantitative pharmacokinetic reports found in primary literature.</p><h4>References</h4><ol><li><p>Freundlich, M, &amp; Abitbol, CL (2017). Oral paricalcitol: expanding therapeutic options for pediatric chronic kidney disease patients. <i>Pediatric nephrology (Berlin, Germany)</i> 32(7) 1103–1108. DOI:<a href=\"https://doi.org/10.1007/s00467-017-3675-7\">10.1007/s00467-017-3675-7</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/28451892/\">https://pubmed.ncbi.nlm.nih.gov/28451892</a></p></li><li><p>Patel, H, et al., &amp; Srinivas, NR (2017). Comparative Pharmacokinetics of Cholecalciferol in Dogs from 2 Different Oral Formulations Using Corrective Measures to Overcome Interference from Endogenous Cholecalciferol. <i>Drug research</i> 67(7) 388–395. DOI:<a href=\"https://doi.org/10.1055/s-0043-101527\">10.1055/s-0043-101527</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/28445901/\">https://pubmed.ncbi.nlm.nih.gov/28445901</a></p></li><li><p>Dennis, VC, &amp; Albertson, GL (2006). Doxercalciferol treatment of secondary hyperparathyroidism. <i>The Annals of pharmacotherapy</i> 40(11) 1955–1965. DOI:<a href=\"https://doi.org/10.1345/aph.1G523\">10.1345/aph.1G523</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/17062838/\">https://pubmed.ncbi.nlm.nih.gov/17062838</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A11CC01;
